Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access


Study to assess the role of bromocriptine in treatment of diabetes mellitus

Anuj Kumar Pathak, Subodh Kumar, Manish Kumar, Harihar Dikshit.

Background: Bromocriptine is a dopamine D2 receptor agonist and a sympatholytic agent used very frequently in treatment of hyperprolactinemia, Parkinsonism and acromegaly. Its quick release formulation has been approved for treatment of type 2 diabetes mellitus as an adjunct to diet and exercise. This study evaluated the antihyperglycemic effect of quick release bromocriptine in alloxan induced diabetic rats.
Methods: 24 albino rats were taken and divided into four groups of six rats in each group. Diabetes was induced in three groups and one group was kept as a control group. After successful induction of diabetes, in remaining three group, first group was given no treatment second group was treated with bromocriptine and the third group was treated with metformin. Fasting blood sugar of all the groups were measured on day 1, 7, 14 and 28 of treatment.
Results: In this study both the treatment groups were found to have significant (P

Key words: Alloxan, Bromocriptine, Fasting blood sugar, Diabetes mellitus

Share this Article

Applied Medical Research


ScopeMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About ScopeMed
License Information
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.
Scopemed Buttons